This article is more than 5 years old. Information may no longer be current.

Regenxbio completes dosing in phase 1 trial of gene therapy for wet AMD

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Dosing is complete in a phase 1 clinical trial of RGX-314, a gene therapy treatment for wet age-related macular degeneration, according to a press release from Regenxbio.

The fourth cohort of six patients brings the total number of subjects in the dose-escalation trial to 24, the release said. The multicenter, open-label, multiple-cohort clinical trial is assessing the safety and tolerability of RGX-314 as a one-time therapy for patients with previously treated wet AMD and is being completed at seven retinal surgery centers across the United States.

“We continue to be encouraged by the positive interim data for RGX-314 and the potential of NAV AAV8 gene therapy as a one-time treatment for wet AMD,” Stephen Yoo, MD, Regenxbio chief medical officer, said in the release.

Interim study results are expected to be announced at Retina Subspecialty Day during the American Academy of Ophthalmology meeting later this month.